Collectively, these data may inspire a new wave of clinical investigation that will provide important insights into the clinical benefits of eliminating immunosuppression and preventing therapy resistance of ovarian cancer by targeting the CD44/STAT3 axis in different TME resident cell types. Here, CD44 is linked to ovarian carcinoma.